Axonics, Inc. (AXNX)
| Market Cap | 2.35B |
| Revenue (ttm) | 194.34M |
| Net Income (ttm) | -80.23M |
| Shares Out | 47.07M |
| EPS (ttm) | -1.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 414,345 |
| Open | 50.56 |
| Previous Close | 49.31 |
| Day's Range | 47.72 - 50.94 |
| 52-Week Range | 38.41 - 79.81 |
| Beta | 0.51 |
| Analysts | Buy |
| Price Target | 72.55 (+45.3%) |
| Earnings Date | May 5, 2022 |
About AXNX
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and ...
Financial Performance
In 2021, Axonics's revenue was $180.29 million, an increase of 61.64% compared to the previous year's $111.54 million. Losses were -$80.07 million, 45.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for AXNX stock is "Buy." The 12-month stock price forecast is 72.55, which is an increase of 45.27% from the latest price.
News
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates
Axonics (AXNX) delivered earnings and revenue surprises of 27.54% and 7.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Axonics® Reports First Quarter 2022 Financial Results
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Analysts Estimate Axonics Modulation Technologies (AXNX) to Report a Decline in Earnings: What to Look Out for
Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axonics® to Participate in BofA Securities 2022 Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Axonics® to Report First Quarter 2022 Financial Results on May 5
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Axonics® Launches Direct to Consumer Television Advertising Campaign
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Axonics Modulation Technologies (AXNX) Reports Q4 Loss, Tops Revenue Estimates
Axonics (AXNX) delivered earnings and revenue surprises of 5.56% and 6.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Axonics® Reports Fourth Quarter and Fiscal Year 2021 Financial Results
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Earnings Preview: Axonics Modulation Technologies (AXNX) Q4 Earnings Expected to Decline
Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axonics® to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 24
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Axonics® to Participate in SVB Leerink Virtual Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
New Study Finds More Than 60% of Adult Women in the U.S. Experience Urinary Incontinence
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Axonics (AXNX) Soars 7.4%: Is Further Upside Left in the Stock?
Axonics (AXNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2021 Revenue
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Axonics® CEO Raymond W. Cohen Receives Lifetime Entrepreneurial Achievement Award by the Southern California Biomedic...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Axonics® Ranked the Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Deloitte Unveils 2021 North America Technology Fast 500 Rankings
SAN FRANCISCO, Nov. 17, 2021 /PRNewswire/ -- Deloitte today released its "North America Technology Fast 500," an annual ranking of the fastest-growing North American companies in the technology, media, ...
Axonics® to Participate in Piper Sandler Virtual Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Axonics Modulation Technologies (AXNX) Reports Q3 Loss, Misses Revenue Estimates
Axonics (AXNX) delivered earnings and revenue surprises of 17.39% and -3.83%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Axonics® Reports Third Quarter 2021 Financial Results
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Axonics® Ranked the Fastest Growing Publicly Traded Company in Orange County
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Axonics® to Report Third Quarter 2021 Financial Results on November 4
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...
Axonics® Provides Additional Update on Inter Partes Review Proceedings
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...